Makes Revi, an implantable tibial neuromodulation system for urgency urinary incontinence. FDA granted the De Novo in August 2023 and codified the device type as Class II in September 2026.
One email, every morning
THE MORNING BRIEF
New clearances, funding rounds and regulatory moves for device founders, and every new how-to guide and template as it lands. No noise, no login.
✓
You're in. The next morning brief lands in your inbox.
Unsubscribe anytime. We never sell the list.